Citigroup
MDGL icon

Citigroup’s Madrigal Pharmaceuticals MDGL Stock Holding History

Citigroup’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.67M Buy
18,000
+9,000
+100% +$4.61M ﹤0.01% 1646
2026
Q1 		$4.71M Hold
9,000
– – ﹤0.01% 2025
2025
Q4 		$5.24M Sell
9,000
-18,000
-67% -$9.19M ﹤0.01% 1974
2025
Q3 		$12.4M Buy
27,000
+500
+2% +$187K 0.01% 1346
2025
Q2 		$8.02M Sell
26,500
-13,500
-34% -$4.02M ﹤0.01% 1533
2025
Q1 		$13.2M Buy
40,000
+31,400
+365% +$10.3M 0.01% 1192
2024
Q4 		$2.65M Sell
8,600
-104,100
-92% -$29.3M ﹤0.01% 2574
2024
Q3 		$23.9M Buy
112,700
+50,100
+80% +$12.8M 0.01% 854
2024
Q2 		$17.5M Buy
+62,600
New +$14.9M 0.01% 947
2024
Q1 		– Sell
-5,000
Closed -$1.16M – 5771
2023
Q4 		$1.16M Hold
5,000
– – ﹤0.01% 2697
2023
Q3 		$730K Buy
5,000
+4,500
+900% +$847K ﹤0.01% 2767
2023
Q2 		$116K Hold
500
– – ﹤0.01% 4175
2023
Q1 		$121K Sell
500
-3,000
-86% -$817K ﹤0.01% 3946
2022
Q4 		$1.02M Buy
+3,500
New +$342K ﹤0.01% 2591
2022
Q3 		– Sell
-17,900
Closed -$1.28M – 6124
2022
Q2 		$1.28M Buy
+17,900
New +$1.32M ﹤0.01% 2424

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup's MDGL Position: Q2 2026 in Review

Citigroup increased its Madrigal Pharmaceuticals (MDGL) stake by 46% in Q2 2026, buying an estimated $5.98M and bringing the position to 37,255 shares worth $20M. The position accounts for 0.01% of the portfolio, ranked #1172.

Citigroup first reported a position in MDGL in Q2 2013 and has held it in 49 quarters since. The position peaked at $30.3M in Q4 2024. 415 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Citigroup held 37,255 shares of Madrigal Pharmaceuticals worth $20M as of Q2 2026.
  • Citigroup bought 11,666 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $5.98M.
  • Madrigal Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q2 2026, its #1172 holding.
  • Citigroup first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • Citigroup's Madrigal Pharmaceuticals position peaked at $30.3M in Q4 2024.
  • 415 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.